MIRA PHARMACEUTICALS, INC. COMMON STOCK

NASDAQ: MIRA (MIRA Pharmaceuticals, Inc.)

最近更新时间: 昨天, 9:55AM

0.660

0.01 (1.77%)

前收盘价格 0.648
成交量 90,523
股市价格/股市净资产 (P/B) 3.34
52周波幅
0.510 (-22%) — 1.69 (156%)
稀释每股收益 (EPS TTM) -0.470
总债务/股东权益 (D/E MRQ) 0.04%
流动比率 (MRQ) 12.85
营业现金流 (OCF TTM) -6.14 M
杠杆自由现金流 (LFCF TTM) -3.26 M
资产报酬率 (ROA TTM) -193.30%
股东权益报酬率 (ROE TTM) -355.82%

AIStockmoo 评分

1.3
价值 30% 0.0
AI Insight 参考 NA
相对估值 参考 NA
财务健康 参考 0.0
时机 30% 2.8
AI Technical 参考 NA
技术振荡指标 参考 3.0
技术平均移动指标 参考 2.5
K线形态 参考 NA
市场情绪 20% 0.0
分析师共识 参考 0.0
新闻情绪 参考 NA
聪明钱 20% 0.8
内部交易活动 参考 NA
机构资金流 参考 2.1
空头持仓 参考 -2.2
市场环境 ×1.00
宏观环境 参考 -1.3
行业对比大市 (6个月) +10.3%
支柱一致性 ×1.25
不计入评分
价格波动 参考 1.4
最终评分 1.26

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 看涨
Drug Manufacturers - General (全球的) 混合的 看涨
股票 MIRA Pharmaceuticals, Inc. 混合的 混合的

相关股票

股票 市值 DY P/E(TTM) P/B
MIRA - - - 3.34
SNY - 5.01% - 1.40
GILD - 1.93% - 16.00
AMGN - 2.14% - 17.60
GRFS - 1.07% - 0.900
BIIB - - - 1.94

Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.

部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Small Growth
内部持股比例 19.68%
机构持股比例 5.60%

所有权

姓名 日期 持有股份
Cross Staff Investments Inc 30 Sep 2026 359,401
First American Bank 30 Sep 2026 60,000

该时间范围内无数据。

机构

机构持股比例: 7.43%

持仓变动 机构数 股数
增持 8 673,009
减持 12 102,950
新建仓 2 20,841
清仓 6 37,839

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 282,319 1.4
15 Oct 2026 349,714 2.4
30 Sep 2026 408,844 2.4
15 Sep 2026 447,832 1.0
31 Aug 2026 205,296 4.1
14 Aug 2026 211,083 1.5

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

日期 类型 细节
29 Oct 2026 Yahoo Finance Inside Deep Principle: The AI That Runs Its Own Chemistry Experiments to Discover New Materials
HANGZHOU, CHINA / ACCESS Newswire / October 29, 2026 / Inside a lab in Hangzhou, an AI system named Mira recently pushed a single-step reaction's selectivity from 51.82% to 85% in three months, without a chemist manually running the experiments.
29 Oct 2026 Yahoo Finance MIRA Pharmaceuticals Reports Significant Weight and Fat Reduction With Oral SKNY-1 in Obese Mice, Showing Favorable Lean-Mass and Weight-Regain Outcomes Compared With Semaglutide
SKNY-1's Weight Reduction Without Significant Changes in Food Consumption Suggests a Potential Role for Energy Expenditure, Contrasting With Semaglutide's Initial Food-Intake Suppression and Significant Post-Treatment Increase MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc.…
22 Oct 2026 Yahoo Finance MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
Positive IND-Enabling Proof-of-Concept Study Demonstrates Sustained Efficacy Without Observed Tolerance, Reduced Inflammation-Associated Swelling, and Favorable TolerabilityMIAMI, Oct. 22, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage…
21 Oct 2026 Yahoo Finance Modera Launches AI-Powered Platform Mira to Support Tailored Financial Advice for Clients
Modera Wealth Management, LLC ("Modera"), a fee-only wealth management firm serving individuals, families, business owners, and nonprofit organizations, today announced it has launched Mira, a proprietary agentic AI-powered platform. Mira is designed to harmonize data and support tailored financial…
17 Sep 2026 Yahoo Finance MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site InitiationMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral…
16 Sep 2026 Yahoo Finance Copper Giant Identifies Thirteen Targets Beyond the Mocoa Resource and Its Interpreted Extensions
Copper Giant Resources Corp. ("Copper Giant" or the "Company") (TSXV: CGNT) (OTCQX: CGNRF) (FRA: 29H0) today reports the results of an independent geophysical modelling and predictive targeting study completed by Mira Geoscience Ltd. ("Mira") over its Mocoa copper-molybdenum porphyry project in…
01 Sep 2026 Yahoo Finance Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
A landmark clinical study published in Reproductive BioMedicine Online (Bouchard et al., 2026) provides strong diagnostic accuracy validation for at-home quantitative multi-hormone tracking, establishing a major milestone in reproductive healthcare and FemTech.
01 Sep 2026 Yahoo Finance MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND SubmissionMIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a…

近期信号 K线形态与EMA交叉

▲ EMA看涨交叉 上一个交易日 · 13 Nov
短期 · EMA 7/20
7日EMA上穿20日EMA:短期动能转强。

AI 技术分析

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票